Inve India ▾

Shree Ganesh Remedies share price & results

Shree Ganesh Remedies Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q4 FY26
Ownership as of
Sept 2026

Ankleshwar (Gujarat)-based custom synthesis manufacturer of pharmaceutical intermediates and speciality/fine chemicals, built on complex halogenation and reduction chemistry.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue14.4 ₹ crore−41.8% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin23.3 %−6.3 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit1.1 ₹ crore−67.5% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity10.03 %−5.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin6.80 %−0.4 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)-8.75 %+13.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

4 of 6 judged targets kept · 6 open · verdicts reflect calls analysed to Q4 FY26.

Shree Ganesh Remedies Limited management guidance track record on Inve: 12 targets tracked across analysed earnings calls (4 achieved, 2 missed, 6 open).

TargetOriginal wordingSaidLatest callVerdict
EBITDA Margin24 to 26% of operating margins
Call transcript, Q4 FY25 · 21 May 2025		Q4 FY25Q4 FY26:FY26 margins were well above the guided range. H1 margin was 30.8% and Q4 was 34.3%, significantly beating the revised guidance of 26-27%.
Call transcript, Q4 FY26 · 15 May 2026		Achieved
Agrochemical Project Peak Volume TimelinePeak in next 3 to 4 calendar years (approx 2028-2029)
Call transcript, Q4 FY25 · 21 May 2025		Q4 FY25Q4 FY26:No specific update provided on the peak volume timeline for the agrochemical project.
Call transcript, Q4 FY26 · 15 May 2026		Ghosted
Block 7 Commercial ProductionSecond half of FY27
Call transcript, Q2 FY26 · 12 Nov 2025		Q2 FY26Q4 FY26:Timeline pulled forward. Management now expects commercial production to commence in Q2 FY27, earlier than the original H2 FY27 guidance.
Call transcript, Q4 FY26 · 15 May 2026		Revised Up

Source: Inve Guidance Tracker for Shree Ganesh Remedies Limited · to Q4 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Shree Ganesh Remedies Limited's 12 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 9 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹662.1 +4.59% · +₹29.05

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +35.0% 1Y

₹400₹500₹600₹700Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 12 Nov 2025Q4 FY26 — 15 May 2026

1Y: ₹490.6 on 24 Oct 2025 → ₹662.1. High ₹735.55 (23 Sept 2026), low ₹400.4 (27 Jan 2026).

Previous close
₹633.05
Market cap
₹822 Cr
52-week range
₹400.4 – ₹735.55
One year
+34.85%
Price to earnings (TTM to Jun 2026)
53.24×
Return on equity (TTM to Jun 2026)
10.03%

Overview

Symbol
NSE:SGRL
Exchange
NSE
Currency
INR

What Shree Ganesh Remedies Limited does

Based on the company's own presentations, annual report and earnings calls.

Shree Ganesh Remedies manufactures pharmaceutical intermediates and speciality/fine chemicals through complex multi-step chemistry (halogenation, reduction, methylation/alkylation and related reactions) at its Ankleshwar, Gujarat manufacturing site. It earns revenue as a custom synthesis and CRAMS (Contract Research and Manufacturing Services) partner to global pharmaceutical, agrochemical, polymer and electronics customers, moving from small-batch multi-purpose-plant production of established intermediates toward larger-scale, higher-value custom molecules for global majors. The company is expanding capacity at Ankleshwar (new production blocks) and has acquired land at Dahej for future large-scale, capital-intensive custom manufacturing projects.

Segments

  • Pharmaceutical Intermediates
  • Speciality and Fine Chemicals / CRAMS
Manufacturing blocks (Ankleshwar Unit 1)
7 functional blocks (Block 7 under commissioning, targeted H1 FY27; Block 8 added FY24)
Consolidated capacity utilisation
60-70% (Block 8 ~50%)
Export reach
20+ countries, including EU and US
Glass-lined reactors
35 (1,000-25,000 Ltr, incl. 2 cryogenic down to -30°C)
Stainless steel reactors
28 (1,000-15,000 Ltr, incl. 1 cryogenic down to -40°C)
Autoclave reactors
3 (2,000 Ltr, up to 40 bar)
Founded 1995Headquarters Ankleshwar, Gujarat, India Company website

How the price took the results

close before → close after

Q4 FY26
+15.4%
15 May
Q2 FY26
−0.1%
12 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Shree Ganesh Remedies Limited

Free account: one company. Everything above stays public.

Write why you follow Shree Ganesh Remedies Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Shree Ganesh Remedies Limited

Guides on how to read this kind of business and the numbers that matter.